Thank you, Mr. Chair.
My questions are in three areas. I'm wondering how regulatory changes have affected the PMPRB. On June 17, 2006, the government introduced some regulations dealing with data protection, increasing the time for data protection but also reducing the ability to evergreen. I wonder if that has affected your operation in any way.
I will expand on Ms. Brown's comments on the 10%. It is irritating that the 10% commitment is not being followed. I'd like you to discuss that a little more, expand on it, and share with us how we can better deal with that challenge.
Finally, why are generic drugs generally more expensive in Canada than patented drugs? Perhaps you could share some of the surprising results you alluded to. If generic drugs are more expensive, do the big pharmaceutical companies extend the sale of their drugs beyond the patent expiry date? They might as well.